Document text
Principal Investigator: Jasdave Chahal
Organization: TIBA BIOTECH, LLC
Fiscal Year: 2023
Award: $966,637
Funding agency: National Institute of Allergy and Infectious Diseases
Project Abstract
Avian influenza A H7N9 causes severe respiratory illness with a high mortality rate, and its zoonotic capacity
has raised serious concerns over the possibility of a pandemic. The value of vaccines for pandemic-potential
viruses has been demonstrated by the devastating effects of COVID-19 on human health and the economy.
Development of H7 Influenza vaccines has lagged, as pandemic influenza vaccines have generally been
developed with traditional technologies, and low immunogenicity for H7 products in humans has been reported.
The high threat presented by this strain represents a substantial market gap for newer technologies to fill. The
COVID-19 pandemic illustrated the potential of RNA vaccines as a rapid-response platform, but also
demonstrated their limitations. Current generation vaccines relying on lipid nanoparticle (LNP) delivery are
known to elicit unwanted acute inflammatory responses and require ultra-low temperatures for long-term
storage and stable refrigeration at the point-of-care, highlighting the need for new delivery approaches. In
Phase I studies, Tiba Biotech established Proof-of-Principle that an intramuscular immunization of BALB/cJ
mice with a novel, less inflammatory formulation containing a proprietary delivery molecule and highly
immunogenic RNA replicons encoding the H7N9 hemagglutinin (HA), Neuraminidase (NA) and Nucleoprotein
(NP) at a 1:1:1 mass ratio induced immune responses against all antigens. This approach is expected to
increase the immunogenicity and heterotypic protective potential of the vaccine, and the RNABL platform that
is utilized maximizes the safely delivered RNA mass content, protects RNA from degradation, and enables
efficient uptake by cells in vivo. In Phase II, Tiba Biotech plans to further develop the prototype H7N9 vaccine
by evaluating different ratios of RNAs and delivery materials from Tiba’s enhanced RNABL library, developing
manufacturing, scale up and quality control processes for the RNA components of the vaccine, determining
optimal dosing in a mouse model, establishing protective efficacy in a highly relevant ferret challenge model,
and performing preliminary safety assessments and biodistribution studies in rats. These studies will enable a
request for a pre-IND meeting, and this meeting will be used to inform further experiments prior to IND filing
and clinical trials. Ultimately, this vaccine product will have the potential for commercialization and use in
vaccine stockpiling, enabling preparedness in the case of a H7N9 influenza pandemic. In addition, the
prototype composition developed here will serve as a platform into which any outbreak antigen sequences
could be rapidly implemented.
Terms: <Acute><Acylneuraminyl hydrolase><Adjuvant><Antigens><Avian Influenza><BALB/cJ Mouse><Biodistribution><Biotech><Biotechnology><Bird Flu><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 affected><COVID-19 consequence><COVID-19 crisis><COVID-19 effect><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 impact><COVID-19 impacted><COVID-19 pandemic><COVID-19 public health crisis><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Clinical><Clinical Trials><Common Rat Strains><Development><Disease Outbreaks><Dose><Economics><Ferrets><Formulation><Fowl Pest><Fowl Plague><Future><Generations><Goals><Grippe><H7N9><HPLC><Health><Hemagglutinin><High Performance Liquid Chromatography><High Pressure Liquid Chromatography><High Speed Liquid Chromatography><Human><Immune response><Immunity><Immunization><Immunize><Immunological response><Inflammatory><Inflammatory Response><Influenza><Influenza A><Influenza A Virus, H7N9 Subtype><Influenza A virus><Influenza Vaccines><Influenza Viruses Type A><Influenzavirus A><Intracellular Communication and Signaling><Intramuscular><Lead><Libraries><Marketing><Measures><Methods><Mice><Mice Mammals><Modeling><Modern Man><Monitor><Murine><Mus><N-Acylneuraminate Glycohydrolases><Neuraminidase><Non-Polyadenylated RNA><Nucleic Acids><Nucleoproteins><Oligosaccharide Sialidase><Organ><Orthomyxovirus Type A><Outbreaks><Pb element><Phase><Phase I Study><Pre IND FDA meeting><Pre-IND mtg><Preparedness><Process><Proteins><Quality Control><RNA><RNA Degradation><RNA Gene Products><RNA purification><RNA vaccine><RNA-based vaccine><Rat><Rats Mammals><Rattus><Readiness><Refrigeration><Regimen><Replication Unit><Replicon><Reporting><Research><Ribonucleic Acid><Rodent Model><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Safety><Seasons><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Sialidase><Signal Transduction><Signal Transduction Systems><Signaling><Technology><Toxic effect><Toxicities><Type A Influenza><Vaccines><Virion><Virus><Virus Particle><Zoonoses><Zoonotic><Zoonotic Infection><avian flu><biological signal transduction><cold temperature><commercialization><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 consequence><coronavirus disease 2019 crisis><coronavirus disease 2019 effect><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 impact><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 impact><coronavirus disease-19 pandemic><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><economic><evaluate vaccines><exo alpha sialidase><experiment><experimental research><experimental study><experiments><flexibility><flexible><flu vaccine><flu virus pandemic><flu virus vaccine><heavy metal Pb><heavy metal lead><high risk><host response><immune system response><immunogen><immunogenic><immunogenicity><immunoresponse><in vivo><influenza in birds><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><lipid based nanoparticle><lipid nanoparticle><low temperature><mRNA vaccine><mRNA-based vaccine><manufacture><meeting><meetings><method development><mortality><mouse model><multi-modality><multimodality><murine model><nano particle delivery><nanoparticle delivered><nanoparticle delivery><new technology><novel><novel technologies><pandemic><pandemic concern><pandemic disease><pandemic flu><pandemic influenza><pandemic potential><pandemic prevention><pandemic risk><pandemic strain of influenza><pandemic threat><phase 1 study><point of care><pre-IND consultation><pre-IND discussion><pre-IND meeting><pre-Investigational New Drug meeting><prevent pandemics><protective efficacy><prototype><respiratory><response><safety assessment><scale up><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><uptake><vaccine against flu><vaccine against influenza><vaccine candidate><vaccine development><vaccine efficacy><vaccine evaluation><vaccine safety><vaccine screening><vaccine testing>